知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

65 records (took 0.027 seconds)

    Liquid crystal device
    1.
    发明授权
    Liquid crystal device 失效
    液晶装置

    公开(公告)号：US06603528B1

    公开(公告)日：2003-08-05

    申请号：US09458065

    申请日：1999-12-10

    Applicant: Toshimitsu Tanaka ,  Masayoshi Murata ,  Takahiro Hachisu

    Inventor： Toshimitsu Tanaka ,  Masayoshi Murata ,  Takahiro Hachisu

    IPC: G02F11339

    CPC classification number: G02F1/13394 ,  G02F1/141

    Abstract: A liquid crystal device is constituted by a pair of substantially parallel substrates disposed opposite to each other to leave a gap extending two-dimensionally therebetween including a rectangular wider gap region and a peripheral frame-shaped narrower gap region surrounding the wider gap region, a plurality of spacers disposed in the gap over the wider and narrower gap regions, and a liquid crystal disposed between the pair of substrates so as to form pixels in the wider gap region. The spacers are disposed to have a larger volume per unit substrate area in the wider gap region and a smaller volume per unit substrate area in the narrower gap region, thus providing a uniform cell gap between the substrates.

    Abstract translation: 液晶装置由一对彼此相对布置的基本平行的基板构成，以在其间具有二维延伸的间隙，包括矩形宽的间隙区域和围绕较宽的间隙区域的周边框架形的较窄的间隙区域，多个 设置在更宽和更窄的间隙区域上的间隙中的间隔件，以及设置在该对基板之间的液晶，以在更宽的间隙区域中形成像素。 间隔物设置成在较宽的间隙区域中每单位基底面积的体积更大，并且在较窄的间隙区域中每单位基底面积的体积更小，从而在基底之间提供均匀的细胞间隙。

    3-Alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds
    6.
    发明授权
    3-Alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds 失效
    3-烯基-1-氮杂双环（3.2.0）庚-2-烯-2-羧酸化合物

    公开(公告)号：US4923857A

    公开(公告)日：1990-05-08

    申请号：US312061

    申请日：1989-02-17

    Applicant: Masayoshi Murata ,  Toshiyuki Chiba ,  Akira Yamada

    Inventor： Masayoshi Murata ,  Toshiyuki Chiba ,  Akira Yamada

    IPC: C07D477/00 ,  A61K31/397 ,  A61K31/40 ,  A61P31/04 ,  C07D477/14

    CPC classification number: C07D477/14

    Abstract: The invention relates to an antimicrobial compound of the formula: ##STR1## in which R.sup.1 is carboxy or protected carboxy,R.sup.2 is hydroxy(lower)alkyl or protected hydroxy(lower)alkyl,R.sup.3 and R.sup.4 are each hydrogen or lower alkyl, andR.sup.5 is saturated 4 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) or saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), wherein said aliphatic heterocyclic group may be substituted by one or more suitable substituent(s) selected from a group consisting of hydroxy, protected hydroxy, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, halogen, lower alkoxy, lower alkyl, lower alkoxy(lower)alkyl, imino, protected imino, lower alkylamino, protected lower alkylamino, mono(or di)-(lower)alkylcarbamoyloxy, lower alkylidene, lower alkanimidoyl and imino-protective group, or pharmaceutically acceptable salts thereof.

    Substituted-3,4-dihydro-4-(2,4,6-trime thoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
    7.
    发明授权
    Substituted-3,4-dihydro-4-(2,4,6-trime thoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent 失效
    可用作强心剂，抗高血压，脑血管扩张剂和抗血小板剂的取代-3,4-二氢-4-（2,4,6-三甲氧基苯基亚氨基）-2（1H） - 嘧啶酮

    公开(公告)号：US4612376A

    公开(公告)日：1986-09-16

    申请号：US588902

    申请日：1984-03-12

    Applicant: Takao Takaya ,  Masayoshi Murata ,  Kiyotaka Ito

    Inventor： Takao Takaya ,  Masayoshi Murata ,  Kiyotaka Ito

    IPC: C07D239/47 ,  A61K31/513 ,  A61P7/02 ,  A61P9/04 ,  A61P9/12 ,  C07D239/46 ,  C07D239/02 ,  A61K31/495

    CPC classification number: C07D239/47

    Abstract: New pyrimidine derivatives of the formula: ##STR1## wherein Z is a group selected from ##STR2## in which R.sup.1 and R.sup.2 are each hydrogen, alkenyl, ar(lower)alkyl or lower alkyl optionally substituted with epoxy, hydroxy, amino and/or lower alkylamino and R.sup.5 is lower alkyl,R.sup.3 is hydrogen, aryl optionally substituted with lower alkyl, lower alkoxy and/or halogen, or pyridyl optionally substituted with lower alkyl,R.sup.4 is hydrogen, lower alkyl or phenyl optionally substituted with lower alkoxy, andY is .dbd.O, .dbd.S or .dbd.N--R.sup.6, in which R.sup.6 is lower alkyl; cyclo(lower)alkyl; ar(lower)alkyl optionally substituted with lower alkoxy; N-containing unsaturated heterocyclic group optionally substituted with lower alkyl; or aryl optionally substituted with hydroxy, lower alkyl, halogen or lower alkoxy, in which lower alkoxy substituent may be substituted with epoxy, hydroxy, amino and/or lower alkylamino,provided that Y is .dbd.N--R.sup.6 when R.sup.3 and R.sup.4 are each hydrogen, and Y is .dbd.S or .dbd.N--R.sup.6 when R.sup.1 and R.sup.2 are each hydrogen or lower alkyl and R.sup.3 is phenyl, and pharmaceutically acceptable salts thereof, and processes for preparation thereof and pharmaceutical composition comprising the same.These derivatives and salts thereof are useful as cardiotonic, antihypertensive agent, cerebrovascular vasodilator and anti-platelet agent.

    Abstract translation: 其中Z是选自其中R 1和R 2各自为氢的链烯基，芳基（低级）烷基或任选被环氧基，羟基，氨基和/或烷基取代的低级烷基的基团的新的嘧啶衍生物 低级烷基氨基，R5为低级烷基，R3为氢，任选被低级烷基，低级烷氧基和/或卤素取代的芳基，或任选被低级烷基取代的吡啶基，R4为氢，低级烷基或任选被低级烷氧基取代的苯基，Y 是= O，= S或= N-R6，其中R6是低级烷基; 环（低级）烷基; 任选被低级烷氧基取代的芳（低级）烷基; 任选被低级烷基取代的含N的不饱和杂环基; 或任选被羟基，低级烷基，卤素或低级烷氧基取代的芳基，其中低级烷氧基取代基可被环氧基，羟基，氨基和/或低级烷基氨基取代，条件是当R 3和R 4各自为氢时，Y为= ，当R 1和R 2各自为氢或低级烷基且R 3为苯基时，Y为= S或= N-R 6及其药学上可接受的盐，及其制备方法和包含其的药物组合物。 这些衍生物及其盐可用作强心剂，抗高血压剂，脑血管扩张剂和抗血小板剂。

Patent Agency Ranking